These findings validate RNF5 as a drug target for cancer, and strongly encourage further preclinical development of the RNF5 activator Analog-1 and possibly clinical trials in patients affected by NB and melanoma to address the safety and efficacy. This evidence concerns the gene RNF5 and cancer.